CRISPR rising stars

Andrew Anzalone (Broad Institute), Jennifer Hamilton (Berkeley) and Cameron Myhrvold (Princeton)

December is time for rankings and forecasts. Let’s start with STAT News celebrating young talents who could become the next generation of scientific superstars. Three CRISPR researchers appear among STAT wunderkinds. As a postdoc at the Broad Institute, Andrew Anzalone helped make a key advance by developing prime editing, where the same RNA molecule specifies the target and the desired edit. Jennifer Hamilton, from Berkeley, works on solving one of the major hurdles of CRISPR-based therapies: delivering the genome editor to the desired cells. Cameron Myhrvold, has since worked at the Broad Institute on developing CRISPR-based diagnostics such as CARMEN and is about to start his own lab at Princeton.

Our CRISPR future, according to J. Doudna

The Nobel Prize for CRISPR is one of the most exciting ever assigned in chemistry and one of the most celebrated in the media, for reasons related to the invention and the inventors alike. On the one hand, the technique is changing the practice and the image of genetic engineering. On the other hand, Jennifer Doudna and Emmanuelle Charpentier are not merely great scientists; they are a success story in cracking the glass ceiling and a symbol of the strength of collaboration.

Continue reading

CRISPR milestone: FDA approves first diagnostic test

May 7th 2020 will be remembered as a good day for CRISPR. Yesterday the first CRISPR/Cas-based test received Emergency Use Authorization from the U.S. Food and Drug Administration. The Sherlock SARS-CoV2 kit works by programming a CRISPR enzyme to detect the coronavirus genetic signature, providing results in about one hour. Quickly and cheaply indeed, as the materials for one test cost about $6.

Continue reading

When CARMEN met the coronavirus

Say hello to CARMEN: a massively multiplexed, Cas13-based technology for nucleic acid detection, out yesterday in Nature. Its name stands for Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids, and it allows us to test many amplified samples for the presence of many viral sequences by using miniaturized detection reactions that self-organize in a microwell array. Sars-Cov2 included.

Continue reading

CRISPR application to infectious diseases

CRISPR holds promise for the treatment of cancer and inherited disorders, as you know, but what about infectious diseases? It can do many useful things indeed, according to this review by Jeffrey Strich and Daniel Chertow, published in the Journal of Clinical Microbiology.

Continue reading

Toward a CRISPR-based diagnostics for COVID-19

Do you remember Sherlock? The CRISPR-based platform was heralded in Science as a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. The good news is that Feng Zhang and colleagues are sharing a research protocol, applicable to purified RNA, that may inform the development of a Sherlock test for COVID-19. For more information, visit the McGovern Institute website.

The CRISPR diagnostics era is here

ZikaTest_Paper-based-results-002-1024x576Elementary dear Watson, we should have expected that. The CRISPR wave is hitting diagnostics, with a new high sensitivity detection platform named after Arthur Conan Doyle’s popular detective. The acronym SHERLOCK stands for “Specific High Sensitivity Enzymatic Reporter UnLOCKing”. While the technique is used in thousands of labs to turn genes on and off, CRISPR embarks also on epidemiology and learns how to identify nucleic acids from viral and bacterial pathogens to diagnose infections. The paper published in Science by James Collins, Feng Zhang and colleagues heralds a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. Continue reading